$35.90
2.42% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US0327241065
Symbol
ANAB
Sector
Industry

AnaptysBio, Inc. Stock price

$35.90
+3.82 11.91% 1M
+10.41 40.84% 6M
+14.48 67.60% YTD
+15.98 80.22% 1Y
+9.10 33.96% 3Y
-5.20 12.65% 5Y
+18.90 111.18% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.89 2.42%
ISIN
US0327241065
Symbol
ANAB
Sector
Industry

Key metrics

Market capitalization $1.08b
Enterprise Value $1.11b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 36.50
P/S ratio (TTM) P/S ratio 35.58
P/B ratio (TTM) P/B ratio 99.69
Revenue growth (TTM) Revenue growth 135.59%
Revenue (TTM) Revenue $30.47m
EBIT (operating result TTM) EBIT $-155.05m
Free Cash Flow (TTM) Free Cash Flow $-129.94m
Cash position $350.80m
EPS (TTM) EPS $-6.34
P/E forward negative
P/S forward 33.80
EV/Sales forward 34.68
Short interest 25.44%
Show more

Is AnaptysBio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

AnaptysBio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a AnaptysBio, Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a AnaptysBio, Inc. forecast:

Buy
91%
Hold
9%

Financial data from AnaptysBio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
30 30
135% 135%
100%
- Direct Costs 2.40 2.40
1% 1%
8%
28 28
166% 166%
92%
- Selling and Administrative Expenses 38 38
5% 5%
124%
- Research and Development Expense 143 143
27% 27%
469%
-153 -153
11% 11%
-501%
- Depreciation and Amortization 2.40 2.40
1% 1%
8%
EBIT (Operating Income) EBIT -155 -155
11% 11%
-509%
Net Profit -170 -170
18% 18%
-558%

In millions USD.

Don't miss a Thing! We will send you all news about AnaptysBio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AnaptysBio, Inc. Stock News

Neutral
GlobeNewsWire
9 days ago
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences:
Positive
The Motley Fool
16 days ago
The biotech saw some action thanks in no small part to a new analyst note. This reiterated an existing buy recommendation at a relatively high target price.
Positive
Seeking Alpha
23 days ago
AnaptysBio, Inc. 14-week results from the phase 2b study, using ANB032 for the treatment of patients with moderate-to-severe Atopic Dermatitis, expected in December 2024. The global Atopic dermatitis market is expected to reach $19.49 billion by 2034. Top-line 12-week data from the phase 2b study, using rosnilimab for the treatment of patients with moderate-to-severe rheumatoid arthritis, expec...
More AnaptysBio, Inc. News

Company Profile

AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its products pipeline include ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Head office United States
CEO Daniel Faga
Employees 117
Founded 2005
Website www.anaptysbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today